1-13 of 13
Julian Adams
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract IA-11: Discovery and preclinical activity of IPI‐926, a Hedgehog pathway inhibitor

Free
Julian Adams
Journal: Cancer Research
Cancer Res (2009) 69 (23_Supplement): IA-11.
https://doi.org/10.1158/0008-5472.FBCR09-IA-11
Published: 28 October 2014
View articletitled, Abstract IA-11: Discovery and preclinical activity of IPI‐926, a Hedgehog pathway inhibitor
Journal Articles

Abstract #1710: A novel pharmacodynamic assay to measure Hsp90 target occupancy by the small molecule inhibitors IPI-504 and IPI-493 in tumors

Free
Bonnie Tillotson, John Coco, Nigel Whitebread, Kip West, Kelly Slocum, Brian Thomas, Jennie Ge, Janid Ali, Emmamuel Normant, Jennifer Hoyt, John MacDougall, Jens Sydor, Vito Palombella, Julian Adams, Christian Fritz
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 1710.
Published: 01 May 2009
View articletitled, Abstract #1710: A novel pharmacodynamic assay to measure Hsp90 target occupancy by the small molecule inhibitors IPI-504 and IPI-493 in tumors
Journal Articles

Abstract #4691: The antiproliferative activity of IPI-504 does not depend on the cellular oxidoreductase NQO1

Free
Emmanuel Normant, Mark Douglas, Alice Lim, Kip West, Jie Ge, Andrew Wylie, Christian Fritz, James Porter, Vito Palombella, Michael Curtis, Julian Adams
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 4691.
Published: 01 May 2009
View articletitled, Abstract #4691: The antiproliferative activity of IPI-504 does not depend on the cellular oxidoreductase NQO1
Journal Articles

BNC105P is a vascular disruption agent that exhibits dual mode of action in a number of cancer indications and works additively in combination with bevacizumab.

Free
Gabriel Kremmidiotis, Tina Lavranos, Donna Beaumont, Annabell Leske, Julian Adams, Michael O'Callaghan, Allison Hall, Deanna Bueti, Jelena Gasic, Bernard Flynn
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 1445.
Published: 01 May 2008
View articletitled, BNC105P is a vascular disruption agent that exhibits dual mode of action in a number of cancer indications and works additively in combination with bevacizumab.
Journal Articles

Activity of IPI-926, a potent HH pathway inhibitor, in a novel model of medulloblastoma derived from Ptch/HIC +/- mice

Free
Melissa Pink, Jennifer Proctor, Kimberly Briggs, John MacDougall, Nigel Whitebread, Martin Tremblay, Michael Grogan, Vito Palombella, Alfredo Castro, Julian Adams, Margaret Read, Ian Corcoran-Schwartz, Thomas Harcke, Charles Eberhart, D Watkins, Jens Sydor
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 1588.
Published: 01 May 2008
View articletitled, Activity of IPI-926, a potent HH pathway inhibitor, in a novel model of medulloblastoma derived from Ptch/HIC +/- mice
Journal Articles

A novel HH pathway inhibitor, IPI-926, delays recurrence post-chemotherapy in a primary human SCLC xenograft model

Free
Veronica Travaglione, Craig Peacock, John MacDougall, Karen McGovern, Jill Cushing, Lin Chen Yu, Martin Trudeau, Vito Palombella, Julian Adams, Jared Hierman, Jonathon Rhodes, Wendy Devereux, D Neil Watkins
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4611.
Published: 01 May 2008
View articletitled, A novel HH pathway inhibitor, IPI-926, delays recurrence post-chemotherapy in a primary human SCLC xenograft model
Journal Articles

Activity of IPI-504, a water-soluble HSP90 inhibitor, combined with bortezomib in a human multiple myeloma xenograft model

Free
Melissa M. Pink, Chris S. Pien, Veronica T. Travaglione, Emmanuel Normant, John Patterson, Jeff Tong, Christian Fritz, Roger Pak, Jennifer Cole, Julian Adams, Vito Palombella
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 899–900.
Published: 15 April 2006
View articletitled, Activity of IPI-504, a water-soluble HSP90 inhibitor, combined with bortezomib in a human multiple myeloma xenograft model
Journal Articles

Anti-tumor activity of a novel, water soluble Hsp90 inhibitor IPI-504 in multiple myeloma

Free
Jens R. Sydor, Christine S. Pien, Yilong Zhang, Janid Ali, Marlene S. Dembski, Jennie Ge, Louis Grenier, Jebecka Hudak, Emmanuel Normant, Roger Pak, Jon Patterson, Melissa Pink, Jim Sang, Caroline Woodward, Constantine S. Mitsiades, Kenneth C. Anderson, David S. Grayzel, Jim Wright, Jeffrey K. Tong, Julian Adams, Vito J. Palombella, John A. Barrett
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1449–1450.
Published: 01 May 2005
View articletitled, Anti-tumor activity of a novel, water soluble Hsp90 inhibitor IPI-504 in multiple myeloma
Journal Articles

Drug resistance in a sarcoma xenograft model is overcome by schedule-dependent proteasome inhibition using Velcade™ (Bortezomib, formerly PS-341).

Free
David Ljungman, John Flannery, Rong Liu, Lijun Xia, Julian Adams, Peter Elliott, Margaret Read, Oscar Kashala, James C. Cusack
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 491.
Published: 01 April 2004
View articletitled, Drug resistance in a sarcoma xenograft model is overcome by schedule-dependent proteasome inhibition using Velcade™ (Bortezomib, formerly PS-341).
Journal Articles

Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model

Available to Purchase
Richard LeBlanc, Laurence P. Catley, Teru Hideshima, Suzanne Lentzsch, Constantine S. Mitsiades, Nicholas Mitsiades, Donna Neuberg, Olga Goloubeva, Christine S. Pien, Julian Adams, Deepak Gupta, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Cancer Research
Cancer Res (2002) 62 (17): 4996–5000.
Published: 01 September 2002
View articletitled, Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model
Open the PDF for Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model in another window
Journal Articles

Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341:: Implications for Systemic Nuclear Factor-κB Inhibition

Available to Purchase
James C. Cusack, Jr., Rong Liu, Michael Houston, Karin Abendroth, Peter J. Elliott, Julian Adams, Albert S. Baldwin, Jr.
Journal: Cancer Research
Cancer Res (2001) 61 (9): 3535–3540.
Published: 01 May 2001
View articletitled, Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341:: Implications for Systemic Nuclear Factor-κB Inhibition
Open the PDF for Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341:: Implications for Systemic Nuclear Factor-κB Inhibition in another window
Journal Articles

The Proteasome Inhibitor PS-341 Inhibits Growth, Induces Apoptosis, and Overcomes Drug Resistance in Human Multiple Myeloma Cells

Available to Purchase
Teru Hideshima, Paul Richardson, Dharminder Chauhan, Vito J. Palombella, Peter J. Elliott, Julian Adams, Kenneth C. Anderson
Journal: Cancer Research
Cancer Res (2001) 61 (7): 3071–3076.
Published: 01 April 2001
View articletitled, The Proteasome Inhibitor PS-341 Inhibits Growth, Induces Apoptosis, and Overcomes Drug Resistance in Human Multiple Myeloma Cells
Open the PDF for The Proteasome Inhibitor PS-341 Inhibits Growth, Induces Apoptosis, and Overcomes Drug Resistance in Human Multiple Myeloma Cells in another window
Journal Articles

Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents

Available to Purchase
Julian Adams, Vito J. Palombella, Edward A. Sausville, Jill Johnson, Antonia Destree, Douglas D. Lazarus, Jochen Maas, Christine S. Pien, Samuel Prakash, Peter J. Elliott
Journal: Cancer Research
Cancer Res (1999) 59 (11): 2615–2622.
Published: 01 June 1999
View articletitled, Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents
Open the PDF for Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents in another window